How to Verify Your Insurance Covers TMS Therapy — A Step-by-Step Guide

For most patients considering TMS therapy, the financial question — will my insurance pay for this? — needs to be answered before the clinical conversation can move forward. The good news is that transcranial magnetic stimulation has been covered by Medicare and the major commercial carriers for over a decade. The complicating factor is that coverage is conditional on documentation, and each carrier maintains its own medical-policy criteria. This guide walks through the actual verification process: which questions to ask, which documents to gather, and where each carrier draws the line.

What "covered" actually means for TMS

Insurance coverage for TMS is built on three layers, and a yes at one layer does not guarantee a yes at the next:

• Benefit level — Is TMS a covered benefit under your plan at all? For most commercial plans and Medicare, yes.
• Medical-necessity criteria — Does your clinical situation meet the carrier's documented criteria for that benefit? This is where most denials originate.
• Prior authorization — Has the carrier reviewed your records and issued written approval before treatment begins? Required by virtually every payer.

A patient who skips the second and third layers and starts treatment on the assumption that "TMS is covered" is the patient most likely to receive a surprise bill. The verification process exists to confirm all three layers before any clinical commitment.

The medical-necessity baseline: what every carrier requires

The starting point is the Centers for Medicare & Medicaid Services (CMS) coverage framework. Medicare covers TMS for major depressive disorder when specific clinical criteria are met, and most commercial carriers have aligned their policies closely to that framework.¹ In broad terms, expect to need documentation of:

• A confirmed diagnosis of major depressive disorder (single or recurrent episode), made by a psychiatrist or qualified mental health prescriber.
• A current depressive episode of at least moderate severity, evidenced by a validated rating scale — typically a PHQ-9 ≥20, HDRS ≥17, or MADRS ≥20.
• At least one — most commonly two — failed antidepressant trials at adequate dose and adequate duration within the current episode, from at least two distinct pharmacologic classes. "Adequate duration" generally means a minimum of six weeks at therapeutic dose.
• An adequate trial of evidence-based psychotherapy (commonly required, though some carriers waive this where psychotherapy is contraindicated or inaccessible).
• No clinical contraindication to TMS — most importantly, no personal history of seizure disorder and no ferromagnetic implants within approximately 30 cm of the treatment coil.

Some carriers add their own conditions — for example, documentation of prior inadequate response or intolerance to augmentation strategies, or a minimum number of psychiatric medication trials across the lifetime of the illness. Those carrier-specific layers are where verification is genuinely useful — generic answers will not cover them.

Step 1: Gather the documentation the carrier will ask for

Before any phone call or portal submission, assemble the clinical record. The verification team — whether yours or the clinic's — needs:

• Your insurance card (front and back), or a clear photo of both.
• Subscriber details if you are covered as a dependent.
• The name of your treating psychiatrist and any other mental health prescribers in the current episode.
• A medication list for the current episode, including each antidepressant tried, dose, start and stop dates, reason for discontinuation (non-response, side effects, etc.), and the prescribing clinician.
• Recent PHQ-9 or other rating-scale scores, ideally within the last 30 to 60 days.
• Any prior psychotherapy during the current episode (clinician, modality, dates).
• A clinical summary or recent chart note from your psychiatrist supporting the diagnosis and TRD status.

A complete file at the start saves weeks. Incomplete files are the single most common reason prior-authorization decisions are delayed.

Step 2: Call your carrier — or have the clinic do it

A first verification call to the member-services number on your insurance card establishes the benefit-level basics. Useful questions:

• Is TMS therapy a covered benefit under my plan for major depressive disorder?
• What CPT codes are typically billed for TMS — 90867, 90868, 90869 — and is each covered?
• Is prior authorization required? Through what entity — the carrier directly, or a behavioral-health vendor?
• What is the medical-policy reference number for TMS so I can review the criteria?
• What is my deductible status year-to-date, and what is the expected coinsurance or copay per session?

Write down the representative's name, the reference number for the call, and the date. Carriers honor what is documented in their call records when disputes arise later.

For most patients, the more efficient path is to let the clinic handle this. Submitting your insurance details through the coverage verification form puts the call into the hands of a team that does these verifications daily and knows which carrier-specific phrasing produces a clean answer.

Step 3: Prior authorization — what to expect

Prior authorization (PA) is a written approval from the carrier that confirms the proposed treatment meets the carrier's medical-necessity criteria before services are rendered. For TMS, the PA submission packet typically includes:

• A completed PA form (carrier-specific)
• The treating psychiatrist's clinical summary documenting diagnosis, severity, and treatment history
• The medication-trial log
• Rating-scale evidence
• A statement of TMS candidacy (no contraindications)

Turnaround time depends on plan type. Under CMS's 2024 Interoperability and Prior Authorization Final Rule (CMS-0057-F), Medicare Advantage, Medicaid managed care, CHIP, and ACA marketplace QHPs operate on 72 hours for expedited review and 7 calendar days for standard review. Commercial and ERISA plans not covered by that rule typically run 5 to 15 business days for standard review. The carrier will issue either an approval (with an authorization number, an approved number of sessions, and a validity window) or a denial (with an appealable reason). Approvals are typically issued for the full 36-session course; some carriers approve in phases (e.g., the first 30 sessions, with the final 6 contingent on documented response).

Step 4: Understanding the cost side

Even with a PA approval, patient cost-share depends on plan structure:

• Deductible — the amount you pay out of pocket before the plan begins to pay. TMS sessions billed before deductible is met are largely your responsibility (subject to the negotiated rate, not the list price).
• Coinsurance — the percentage of the negotiated rate you pay after deductible is met (commonly 20–40% for in-network behavioral health, higher out-of-network).
• Copay — a flat per-visit amount in some plans, in place of coinsurance.
• Out-of-pocket maximum — the annual cap on what you pay; once met, the plan covers 100%.

For a typical TMS course of 36 sessions, total patient responsibility varies widely. Before scheduling, the verification call should produce a defensible estimate of your full out-of-pocket cost for the course — not just a per-session number.

When verification produces a "no"

A denial is not always final. The most common appealable reasons are:

• Insufficient documentation of failed medication trials — often a paperwork problem rather than a clinical one; the appeal supplies the missing details.
• Psychotherapy criterion not satisfied — sometimes addressable by documenting a clinical reason psychotherapy is not appropriate.
• Out-of-network provider — if the clinic is out-of-network with the patient's plan, single-case agreements are sometimes available.

A psychiatrist-led appeal, with a peer-to-peer review where the carrier allows, reverses a meaningful share of initial denials.

Key takeaways

• Insurance coverage for TMS therapy is built on three layers — benefit level, medical-necessity criteria, and prior authorization — and a yes at the benefit level does not guarantee approval.
• CMS coverage for TMS sets the framework most commercial carriers follow: a confirmed MDD diagnosis, moderate-to-severe current episode, and ≥1–2 failed antidepressant trials of adequate dose and duration.
• Before any verification call, assemble the medication-trial log, recent rating-scale scores, and a clinical summary from your psychiatrist — incomplete files are the leading cause of PA delays.
• Expect prior authorization to take 5 to 15 business days; most approvals cover the full 36-session course.
• Even with PA approval, total patient cost depends on deductible, coinsurance, and out-of-pocket maximum — get a course-level estimate, not just a per-session figure.

For patients in Anaheim, Orange County, and the broader 30-mile radius, our team handles verification and prior authorization on your behalf — including the medication-trial log, clinical summaries, and carrier-specific PA forms. Start with the insurance verification form and we will confirm coverage and expected cost before scheduling.

Sources / Further reading